

anomalies, no increased risks in heart, limb or genital system were found.

**Conclusion** There are similar risks of major congenital anomalies in children born to women with and without IBD. No evidence of potential teratogenic effects of 5-aminosalicylic acid, steroids or azathioprine was found in this study. Previous guidance that women may be advised to continue these medications remains appropriate.

**Disclosure of Interest** None Declared

#### OC-074 THE ROLE OF THE FUNGAL MICROBIOTA IN THE PATHOGENESIS OF DE-NOVO PAEDIATRIC INFLAMMATORY BOWEL DISEASE USING NEXT GENERATION SEQUENCING

doi:10.1136/gutjnl-2013-304907.073

<sup>1</sup>R Hansen, <sup>1</sup>I Mukhopadhyay, <sup>2</sup>C Meharg, <sup>3</sup>R Russell, <sup>1</sup>S Berry, <sup>1</sup>E El-Omar, <sup>1</sup>G Hold. <sup>1</sup>Division of Applied Medicine, Aberdeen University, Aberdeen; <sup>2</sup>Queens University Belfast, Belfast; <sup>3</sup>Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow, UK

**Introduction** Paediatric Inflammatory bowel disease (IBD) incidence is rising worldwide. Recently the role of the gut microbiota has been recognised as pivotal in disease pathogenesis. IBD microbial studies to date have focused on bacterial diversity assessment in established disease cohorts, with limited studies in treatment naive patients. In contrast to bacteria, the exact role of the colonising fungi and their pathogenic potential has not been fully explored. The aim of the study was to examine candidate fungal triggers at disease onset in children with IBD using pyrosequencing, utilising the Bacteria in Inflammatory bowel disease in Scottish Children Undergoing Investigation before Treatment (BISCUIT) study cohort.

**Methods** 128 children undergoing colonoscopy were approached from three Scottish paediatric centres (Aberdeen, Glasgow and Dundee) with 100 ultimately recruited and biopsied; 44 IBD (comprising Crohn's disease (CD; 29), ulcerative colitis (UC; 13) and IBD-type unspecified (2)), 42 normal colon controls (NCC) and 14 "others". All IBD patient samples were taken from inflamed tissue. Fungal DNA was amplified on a reduced cohort of 37 recruits (13 CD, 12 UC, 12 NCC) using 18S rDNA primers. Roche 454 Titanium sequencing was conducted by NewGene (Newcastle, UK). Data analysis was performed using QIIME version 1.3.0 workflow. Taxonomy assignment of operational taxonomic units (OTUs) was performed according to ribosomal database project taxonomy. OTU tables were rarefied at 3,000 reads.

**Results** Fungal DNA was amplifiable from 7 patient samples, 6 children with a diagnosis of IBD – 4 with CD (BISCUIT1, 31, 62 and 89), 2 children with UC (BISCUIT33 and 104) and 1 NCC (BISCUIT 27). Fungal diversity was assessed in all paediatric samples alongside three adult samples to act as comparison. The adult samples comprised 1 patient with UC (2UC21Aa) and 2 NCC (GH4 and GH9). Phylum level analysis indicated that all fungal sequences belonged to the Ascomycota and Basidiomycota phyla. Control patients contained predominantly Ascomycota sequences (> 80% of sequences in all patients) whilst 6/7 IBD patients contained exclusively Basidiomycota species. Genus level analysis was undertaken and there was no similarity between fungal profiles from the paediatric and adult samples.

**Conclusion** By using robust methodology we have characterised the IBD "fungal microbiota" at diagnosis in children. Based on the current study, it would appear that a distinctly altered fungal species profile is present at IBD disease presentation. Further work should now focus on expanding this study and identifying how to beneficially modify the microbiota using established and novel IBD treatments.

**Disclosure of Interest** None Declared

## Endoscopy symposium: how I do it - ERCP

### OC-075 ANALYSIS OF LONG-TERM OUTCOMES AFTER ENDOSCOPIC RADIOFREQUENCY ABLATION FOR BILE DUCT STRICTURES IN PANCREATIC MALIGNANCY SUGGESTS POTENTIAL SURVIVAL BENEFIT

doi:10.1136/gutjnl-2013-304907.074

<sup>1,2</sup>Y Kallis, <sup>2</sup>N Phillips, <sup>3</sup>A Steel, <sup>2</sup>H Kaltsidis, <sup>2</sup>J Nicholls, <sup>2</sup>L Jiao, <sup>2</sup>P Vlavianos, <sup>2</sup>N Habib, <sup>2</sup>D Westaby. <sup>1</sup>Endoscopy, Royal London Hospital, Barts Health NHS Trust; <sup>2</sup>HPB Unit, Imperial College Healthcare NHS Trust; <sup>3</sup>Gastroenterology, Chelsea & Westminster NHS Foundation Trust, London, UK

**Introduction** Pancreatic carcinoma carries a poor prognosis with only 10–20% of patients amenable to attempts at curative surgery at presentation. Biliary obstruction is a common complication and many patients will require self-expanding metal stent (SEMS) insertion for definitive decompression. A recent pioneering phase I/II study in our tertiary referral centre demonstrated excellent safety and 90d stent patency with endobiliary radiofrequency ablation (RFA) as an adjunct to SEMS insertion. The longer-term impact of this novel endoscopic treatment modality on biliary drainage and patient survival in advanced pancreatic carcinoma is unknown.

**Objective** To investigate the longer-term efficacy of endobiliary RFA in the management of malignant bile duct obstruction associated with inoperable pancreatic carcinoma.

**Methods** Retrospective cohort analysis of 23 patients with unresectable pancreatic carcinoma undergoing RFA + SEMS insertion, and 46 matched controls undergoing SEMS insertion alone, for malignant biliary obstruction in a single tertiary referral centre. Patients were stringently matched for age, sex, metastases, ASA/co-morbidities, and intention to treat with palliative chemotherapy. Survival, maintenance of stent patency, and procedure-related complications were assessed.

**Results** RFA and control groups were closely matched- age 68.9 +/- 9.0y vs. 69.8 +/- 9.9y,  $p = 0.791$ ; ASA 2.35 +/- 0.65 vs. 2.54 +/- 0.50,  $p = 0.086$ ; metastases at treatment 9/23 (39.1%) vs. 18/46 (39.1%),  $p = 0.800$ ; chemotherapy 16/23 (69.6%) vs. 24/46 (52.2%),  $p = 0.203$ . Median survival was 227d after RFA vs. 123.5d in controls (HR 0.633 CI 0.378–1.060,  $p = 0.011$ ). RFA was independently predictive of survival at 90d (OR 16.14, CI 1.35–193.18,  $p = 0.028$ ) and 180d (OR 4.25, CI 1.00–18.01,  $p = 0.049$ ). Overall SEMS patency rates were the same across both groups, though more patients were alive with a patent index SEMS after RFA within the first few months (73.9% vs. 41.3% at 4.5m,  $p = 0.012$ ). Complications of RFA were few (1 pancreatitis, 1 cholangitis), with a median post-procedure inpatient stay of 1d (1–8).

**Conclusion** In the single largest case series to date, endobiliary RFA was found to be a safe and efficacious adjunctive treatment in the management of patients with advanced pancreatic malignancy and biliary obstruction, and demonstrated potential early survival benefit. These data suggest that endobiliary RFA could be an additional treatment option in advanced pancreatic carcinoma, and form the basis from which future prospective clinical trials of this novel treatment modality can be designed.

**Disclosure of Interest** Y. Kallis: None Declared, N. Phillips: None Declared, A. Steel: None Declared, H. Kaltsidis: None Declared, J. Nicholls Shareholder of: EMcision Ltd UK, L. Jiao: None Declared, P. Vlavianos: None Declared, N. Habib Shareholder of: EMcision Ltd UK, D. Westaby: None Declared.

### OC-076 SYRINGE SIZE INFLUENCES THE AMOUNT OF MIDAZOLAM ADMINISTERED DURING SEDATED ENDOSCOPY

doi:10.1136/gutjnl-2013-304907.075

<sup>1</sup>D Haldar, <sup>1</sup>N Quraishi, <sup>1</sup>K Glover, <sup>1</sup>S Keen, <sup>1</sup>A D Farmer. <sup>1</sup>Gastroenterology, Shrewsbury & Telford NHS Trust, Telford, UK